Compounds > 3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide

3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide and Neoplasms

3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide has been researched along with Neoplasms* in 3 studies

Reviews

1 review(s) available for 3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide and Neoplasms

Article	Year
Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. Journal of medicinal chemistry, 2014, Jul-10, Volume: 57, Issue:13 Sphingosine kinase (SphK) is an oncogenic lipid kinase that regulates the sphingolipid metabolic pathway that has been shown to play a role in numerous hyperproliferative/inflammatory diseases. The SphK isoforms (SphK1 and SphK2) catalyze the conversion of the proapoptotic substrate d-erythrosphingosine to the promitogenic/migratory product sphingosine 1-phosphate (S1P). Accumulation of S1P has been linked to the development/progression of cancer and various other diseases including, but not limited to, asthma, inflammatory bowel disease, rheumatoid arthritis, and diabetic nephropathy. SphK therefore represents a potential new target for developing novel therapeutics for cancer and other diseases. This finding has stimulated the development and evaluation of numerous SphK inhibitors over the past decade or so. In this review, we highlight the recent advancement in the field of SphK inhibitors including SphK1 and SphK2 specific inhibitors. Both sphingolipid based and nolipidic small molecule inhibitors and their importance in treatment of cancer and other diseases are discussed. Topics: Clofibrate; Drug Combinations; Enzyme Inhibitors; Humans; Isoenzymes; Lysophospholipids; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Practolol; Sphingosine	2014

Article

Year

Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.

Journal of medicinal chemistry, 2014, Jul-10, Volume: 57, Issue:13

Sphingosine kinase (SphK) is an oncogenic lipid kinase that regulates the sphingolipid metabolic pathway that has been shown to play a role in numerous hyperproliferative/inflammatory diseases. The SphK isoforms (SphK1 and SphK2) catalyze the conversion of the proapoptotic substrate d-erythrosphingosine to the promitogenic/migratory product sphingosine 1-phosphate (S1P). Accumulation of S1P has been linked to the development/progression of cancer and various other diseases including, but not limited to, asthma, inflammatory bowel disease, rheumatoid arthritis, and diabetic nephropathy. SphK therefore represents a potential new target for developing novel therapeutics for cancer and other diseases. This finding has stimulated the development and evaluation of numerous SphK inhibitors over the past decade or so. In this review, we highlight the recent advancement in the field of SphK inhibitors including SphK1 and SphK2 specific inhibitors. Both sphingolipid based and nolipidic small molecule inhibitors and their importance in treatment of cancer and other diseases are discussed.

Topics: Clofibrate; Drug Combinations; Enzyme Inhibitors; Humans; Isoenzymes; Lysophospholipids; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Practolol; Sphingosine

2014

Trials

1 trial(s) available for 3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide and Neoplasms

Article	Year
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-15, Volume: 23, Issue:16 Topics: Adamantane; Adult; Aged; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Treatment Outcome; Vomiting; Young Adult	2017

Article

Year

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-15, Volume: 23, Issue:16

Topics: Adamantane; Adult; Aged; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Treatment Outcome; Vomiting; Young Adult

2017

Other Studies

1 other study(ies) available for 3-(4-chlorophenyl)-adamantane-1-carboxylic-acid-(pyridin-4-ylmethyl)amide and Neoplasms

Article	Year
Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy. International journal of molecular sciences, 2022, Oct-29, Volume: 23, Issue:21 Topics: Animals; Cell Line, Tumor; Cisplatin; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasms	2022